Central nervous system pharmacokinetics of high-dose cytosine arabinoside
JA Lopez, E Nassif, P Vannicola, JG Krikorian… - Journal of Neuro …, 1985 - Springer
JA Lopez, E Nassif, P Vannicola, JG Krikorian, RP Agarwal
Journal of Neuro-Oncology, 1985•SpringerThe cerebrospinal fluid (CSF) pharmacokinetics of cytosine arabinoside (Ara-C) was
determined in 8 patients with metastatic cancer in the central nervous system. High dose (3
gm/M 2) one-hour intravenous infusions of Ara-C were given with serial CSF sampling
obtained from indwelling Ommaya reservoirs. CSF was analyzed by high pressure liquid
chromatography. Mean Ara-C elimination half life of 140 minutes in CSF was eight times
longer than that in plasma. The peak mean CSF concentration of Ara-C (2. l ug/ml) was …
determined in 8 patients with metastatic cancer in the central nervous system. High dose (3
gm/M 2) one-hour intravenous infusions of Ara-C were given with serial CSF sampling
obtained from indwelling Ommaya reservoirs. CSF was analyzed by high pressure liquid
chromatography. Mean Ara-C elimination half life of 140 minutes in CSF was eight times
longer than that in plasma. The peak mean CSF concentration of Ara-C (2. l ug/ml) was …
Summary
The cerebrospinal fluid (CSF) pharmacokinetics of cytosine arabinoside (Ara-C) was determined in 8 patients with metastatic cancer in the central nervous system. High dose (3 gm/M2) one-hour intravenous infusions of Ara-C were given with serial CSF sampling obtained from indwelling Ommaya reservoirs. CSF was analyzed by high pressure liquid chromatography. Mean Ara-C elimination half life of 140 minutes in CSF was eight times longer than that in plasma. The peak mean CSF concentration of Ara-C (2.l ug/ml) was about 7% of the plasma concentration (30 ug/ml).
A total of 28 treatment courses were administered with minimal hematopoietic, gastrointestinal and neurological toxicities. A schedule of administration of 2 high-dose treatments 12 hours apart repeated every two weeks should maintain cytotoxic CSF concentrations which could prove useful in the management of CNS leukemia and lymphoma.
Springer